Fig 1.
Observed rates of cognitive impairment in group of patients with prostate cancer receiving androgen-deprivation therapy (ADT+) and control group. Criteria for impaired cognitive performance: (A) scoring ≥ 1.5 standard deviations (SDs) below published norms on ≥ two tests or 2.0 SDs below published norms on ≥ one test (group differences in change over time P = .05); (B) scoring ≥ 2.0 SDs below published norms on ≥ one test (group differences in change over time P = .01).